Article
Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER+ breast cancer.
Cancer letters - 28 Sept 2024
Liu Bohan, Liu Yuting, Yang Shuang, Ye Jingwen, Hu Jiajie, Chen Si, Wu Shiyi, Liu Qinqing, Tang Fen, Liu Yiwen, He Yiqing, Du Yan, Zhang Guoliang, Guo Qian, Yang Cuixia
Abstract excerpt
Acquired resistance to endocrine treatments remains a major clinical challenge. In this study, we found that desmoglein-2 (DSG2) plays a major role in acquired endocrine resistance and cellular plasticity in ER+ breast cancer (BC). By analysing the well-established fulvestrant-resistant ER+ BC model using single-cell RNA-seq, we revealed that ER inhibition leads to a specific increase in DSG2 in cancer cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.